CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title	Date of Registration	State
CIMAvax-EGF in different maintenance schemes	12/05/2021	Registered outdated
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab	12/05/2020	Registered outdated
CIMAvax-EGF in Bladder cancer	11/08/2020	Registered outdated
Phyisician Led CIMAvax-EGF lung biomarkers	11/03/2021	Registered outdated
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory	09/07/2018	Registered
Itolizumab for Moderate-to-Severe Psoriasis-phase 3	08/10/2015	Registered
VSSP in metastasic renal cell carcinoma	08/08/2018	Registered
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer	08/07/2015	Registered
VSSP in renal cell carcinoma	08/04/2021	Registered
NGcGM3/VSSP in small cell lung cancer	07/12/2016	Registered outdated
NGcGM3/VSSP in Metastatic melanoma	07/12/2016	Registered
14F7 in chronic B-cell lymphoproliferative syndrome	07/03/2018	Registered
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma	05/11/2013	Registered outdated
Nimotuzumab cold kit for the immunodiagnosis of solid tumors	05/10/2018	Registered
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma	05/09/2017	Registered
CIMAVax EGF in Lung Cancer in PHC. Phase IV	05/08/2014	Registered
Dose scale-up and cohort expansion with the therapeutic mAb 14F7	04/12/2015	Registered outdated
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I	03/11/2017	Registered
CIMAvax-EGF-Platelets-Adults- Lung Cancer	03/08/2018	Registered
Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS)	03/03/2023	Registered

Registered Trials

Registration process

CENTER OF MOLECULAR IMMUNOLOGY

About the RPCEC

Useful resources